UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 orOR 15(d) of The Securities Exchange Act of 1934

Date of ~~the~~Report ~~Securities~~(Date ~~Exchange~~of ~~Act~~earliest ofevent ~~1934~~reported): August 1, 2023

Date of Report (Date of earliest event reported): July 31, 2023

EQRX, INC.

(Exact name of ~~Registrant~~registrant as ~~Specified~~specified in ~~Its~~its ~~Charter~~charter)

Delaware	001-40312	86-1691173
(State or Other Jurisdictionof Incorporation)	(CommissionFile Number)	(IRS EmployerIdentification No.)
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
50 Hampshire StreetCambridge, Massachusetts		02139
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 617-315-2255

50 Hampshire Street, Cambridge, MA		02139
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: 617-315-2255

Not Applicable

(Former ~~Name~~name or ~~Former~~former ~~Address~~address, if ~~Changed~~changed ~~Since~~since last ~~Last Report~~report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☒¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001 per share	EQRX	The Nasdaq Global Market
Warrants to purchase one share of common stock at an exercise price of $11.50	EQRXW	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐ ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ¨

Item 1.0102 ~~Entry~~Termination ~~into~~of a Material Definitive Agreement.

~~Merger Agreement~~ G1 Therapeutics

On August ~~July 31~~1, 2023, EQRx, Inc., ~~a Delaware corporation~~ (“EQRx”), ~~Revolution~~provided ~~Medicines,~~written ~~Inc.,~~notice ato ~~Delaware~~G1 ~~corporation~~Therapeutics (~~“Revolution Medicines”~~G1), ~~Equinox Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary~~ of ~~Revolution~~its ~~Medicines~~termination ~~(“Merger Sub I”), and Equinox Merger Sub II LLC, a Delaware limited liability company and a direct, wholly owned subsidiary~~ of ~~Revolution Medicines (“Merger Sub II”), entered into an Agreement and Plan of Merger (~~the ~~“Merger~~Exclusive ~~Agreement”).~~License ~~Pursuant to the Merger~~ Agreement, dated ~~and~~July ~~subject to the satisfaction or waiver of the conditions specified therein~~22, ~~Merger~~2020 ~~Sub~~between IEQRx ~~will be merged with~~ and ~~into~~G1 ~~EQRx~~ (the ~~“First~~G1 ~~Merger”~~Agreement), ~~with~~which ~~EQRx~~termination surviving the First Merger as a direct, wholly owned subsidiary of Revolution Medicines (the “Surviving Corporation”), and as soon as practicable following the First Merger, the Surviving Corporation will be ~~merged~~effective ~~with~~in ~~and~~accordance ~~into Merger Sub II,~~ with ~~Merger~~the ~~Sub~~terms ~~II surviving as a direct, wholly owned subsidiary~~ of ~~Revolution~~such agreement. ~~Medicines~~The ~~(together~~parties ~~with~~are ~~the~~in ~~First~~discussions ~~Merger,~~regarding ~~the~~any ~~“Mergers”).~~transition activities.

~~The~~Under the ~~boards~~G1 ofAgreement, ~~directors~~EQRx ofacquired ~~each~~an exclusive license for the research, development, and commercialization of ~~EQRx~~lerociclib for the treatment, using an oral-only dosage administration by continuous administration for any and ~~Revolution~~all ~~Medicines~~indications ~~have~~in humans ~~approved~~through the ~~Merger~~inhibition ~~Agreement~~of ~~and~~CDK4/6 worldwide, with the ~~transactions~~exception ~~contemplated~~of ~~thereby~~certain territories (such excluded territories, collectively, the G1 Territory). The license agreement also provided EQRx ~~board~~with a non-exclusive license in the G1 Territory to manufacture lerociclib for purposes of ~~directors’~~obtaining regulatory approval ~~was~~for, ~~made~~and ~~upon~~commercialization of lerociclib for the ~~recommendation~~treatment, using an oral-only dosage administration by continuous administration for any and all indications in humans through the inhibition of aCDK4/6 ~~committee~~outside of ~~independent~~the ~~directors~~G1 Territory. EQRx also received an exclusive license to develop lerociclib using an oral-only dosage administration by continuous administration for any and all indications in humans through the inhibition of CDK4/6 at its own cost and expense in its territory.

~~Merger~~EQRx made ~~Consideration~~an upfront non-refundable, non-creditable payment of $20.0 million to G1. Additionally, if EQRx had achieved all of the development and commercialization milestone events under the G1 Agreement, G1 would have been eligible to receive (i) up to $40.0 million in development and regulatory milestone payments, and (ii) up to $250.0 million in sales milestone payments. G1 would have also been entitled to royalty payments under the G1 Agreement.

At the effective time of the First Merger (the “Effective Time”), each share of common stock, par value $0.0001 per share, of EQRx (“EQRx Common Stock”) issued and outstanding immediately prior to the Effective Time (other than the shares that are held by EQRx in treasury or owned by Revolution Medicines, Merger Sub I, Merger Sub II or any wholly owned subsidiary of EQRx or Revolution Medicines) will be converted into the right to receive a number of validly issued, fully paid and non-assessable shares of common stock, par value $0.0001 per share, of Revolution Medicines (the “Parent Common Stock”) equal to the Exchange Ratio (as defined below) (such shares of Parent Common Stock, the “Merger Consideration”). No fractional shares of the Parent Common Stock will be issued in the Mergers, and EQRx stockholders will receive cash in lieu of any fractional shares as part of the Merger Consideration, as specified in the Merger Agreement. The Merger Consideration will consist of a number of shares of Parent Common Stock to be issued (including in respect of converted EQRx Options, EQRx RSU Awards and EQRx Restricted Stock (each as defined below)) determined as follows: (i) 7,692,308 shares of Parent Common Stock, which was determined based on $200.0 million of the aggregate purchase price divided by $26.00 per share of Parent Common Stock; plus (ii) an additional number of shares of Parent Common Stock, which will be determined prior to the special meeting of stockholders of EQRx (the “EQRx Stockholders Meeting”) and will represent $870.0 million of the aggregate purchase price divided by the five trading day volume-weighted average price per share of Parent Common Stock ending on the sixth business day prior to the scheduled EQRx Stockholders Meeting (the “Pre-Meeting VWAP”), applying a six percent discount. Hansoh

~~Also~~On August at1, 2023, EQRx provided written notice to Hansoh (Shanghai) Healthtech Co., LTD. and Jiangsu Hansoh Pharmaceutical Group Company LTD. (Hansoh) of its termination of the ~~Effective~~Strategic ~~Time:~~Collaboration License Agreement dated July 22, 2020 between EQRx and Hansoh (as amended, the Hansoh Agreement), which termination will be effective in accordance with the terms of such agreement. The parties are in discussions regarding any transition activities.

•Under the ~~options~~Hansoh toAgreement, ~~acquire~~EQRx ~~shares~~acquired ofan ~~EQRx~~exclusive ~~Common~~license ~~Stock~~for ~~(“EQRx~~the ~~Options”)~~research, ~~outstanding~~development ~~immediately~~and ~~prior~~commercialization toof ~~the~~aumolertinib, ~~Effective~~a ~~Time~~third generation ~~will~~EGFR beinhibitor, ~~accelerated~~worldwide, inwith ~~full~~the ~~immediately~~exception ~~prior~~of tomainland ~~the~~China, ~~Effective~~Hong ~~Time~~Kong, Macau and ~~each~~Taiwan ~~EQRx~~(the ~~Option~~Hansoh Territory). The Hansoh Agreement also provided EQRx with a ~~per~~non-exclusive ~~share~~license ~~exercise~~in ~~price~~the ~~that~~Hansoh isTerritory ~~less~~to ~~than~~research ~~the~~and ~~Per~~develop ~~Share~~aumolertinib ~~Value~~for ~~(as~~purposes ~~defined~~of obtaining ~~below)~~regulatory (approval for, and commercialization of aumolertinib for use outside of the Hansoh Territory. EQRx made an ~~“In~~upfront non-~~the~~refundable, non-~~Money~~creditable ~~EQRx~~payment ~~Option”)~~under ~~will~~the beHansoh ~~cancelled~~Agreement ~~and~~of ~~converted~~$25.0 ~~into~~million. ~~shares~~Additionally, if EQRx had achieved all of ~~Parent~~the ~~Common~~development and ~~Stock~~commercialization ~~based~~milestone onevents under the ~~Exchange~~Hansoh ~~Ratio~~Agreement, ~~after~~Hansoh ~~taking~~would ~~into~~have ~~account~~been ~~the~~eligible ~~exercise~~to ~~price;~~receive ~~all~~in ~~EQRx~~total ~~Options~~(i) ~~that~~up doto ~~not~~$90.0 million ~~constitute~~in ~~In-the-Money~~development ~~EQRx~~and ~~Options~~regulatory ~~will~~milestone bepayments, ~~terminated~~and at(ii) up to $420.0 million in sales milestone payments. If Hansoh had elected to opt out of sharing certain global development costs in accordance with the ~~Effective~~terms ~~Time~~of ~~for~~the noHansoh ~~consideration;~~Agreement, the ~~“Per~~total ~~Share~~potential ~~Value”~~development and ~~will~~regulatory bepayments ~~equal~~Hansoh would have been eligible to ~~the~~receive ~~Pre-Meeting~~would ~~VWAP,~~have ~~multiplied~~been byreduced to $55.0 million, and the ~~Exchange~~total ~~Ratio~~potential sales ~~(rounded~~milestone ~~down~~payments would have been reduced to ~~the~~$350.0 ~~nearest~~million. ~~whole~~Hansoh ~~cent);~~would have also been entitled to royalty payments under the Hansoh Agreement.

•Item ~~awards~~2.05 ofCosts ~~EQRx~~Associated ~~restricted~~with ~~stock~~Exit ~~units covering EQRx Common Stock (“EQRx RSU Awards”) outstanding immediately prior to the Effective Time, whether~~ or ~~not~~Disposal ~~vested, will be cancelled and converted into shares of Parent Common Stock based on the Exchange Ratio; and~~Activities.

•On July ~~the~~31, ~~vesting~~2023, and in furtherance of ~~each~~its ~~share~~undertakings in that certain Agreement and Plan of ~~restricted~~Merger (the Merger Agreement) by and among EQRx, ~~Common~~Revolution ~~Stock~~Medicines, ~~will~~Inc. beand ~~accelerated~~the inmerger ~~full~~subsidiaries ~~immediately~~party ~~prior~~thereto, tothe EQRx board of directors approved a restructuring plan, which includes the ~~Effective~~termination ~~Time~~of the Hansoh and ~~each~~G1 ~~share~~Agreements (discussed in item 1.02 of ~~restricted~~this ~~EQRx~~Current ~~Common~~Report ~~Stock~~on ~~will~~Form be8-K), ~~treated~~among ~~the~~other agreements, ~~same~~as well as a phased company-wide reduction in headcount, all of which are part of a process to wind down and terminate its current product pipeline and other ~~shares~~research and development. As a result of these actions, EQRx ~~Common~~will ~~Stock~~incur ~~under~~material restructuring payments, such as employee-related termination costs and contract termination costs, all of which are expected to be substantially paid by the end ~~Merger~~of ~~Agreement~~2023, none of which are estimable at this time.

Also at the Effective Time, all outstanding and unexercised warrants to purchase shares of EQRx Common Stock (“EQRx Warrants”) will, in accordance with their terms, be assumed by Revolution Medicines and will cease to represent a warrant exercisable for Parent Common Stock, and will become a warrant exercisable for the Merger Consideration that the holder of such EQRx Warrant would have received if such EQRx Warrant had been exercised immediately prior to the Effective TimeForward-Looking Statements.

~~EQRx~~This Current ~~remains~~Report ~~subject~~on toForm an8-K ~~obligation~~contains ~~under~~forward-looking statements within the ~~definitive~~meaning ~~merger~~of ~~agreement~~federal ~~dated~~securities ~~August~~laws, including the “safe harbor” provisions of 5the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates ~~2021~~and expectations of management of Revolution Medicines, Inc. (~~the~~“Revolution Medicines”) and EQRx, Inc. (“EQRx”) in ~~DeSPAC~~light ~~Merger~~of ~~Agreement~~historical results and trends, current conditions and potential future developments, and are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as “anticipate,”) “expect,” ~~entered~~“project,” ~~into~~“intend,” “believe,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “forecast,” “guidance,” “predict,” “possible,” “potential,” “pursue,” “likely,” and words and terms of similar substance used in connection with ~~its~~any ~~business~~discussion ~~combination~~of future plans, actions or events identify forward-looking statements. All statements, other than historical facts, including express or implied statements regarding the proposed transaction; ~~with~~the ~~EQRx~~conversion ~~International~~of equity interests contemplated by the Merger Agreement; the issuance of common stock of Revolution Medicines contemplated by the Merger Agreement; the expected filing by Revolution Medicines of a registration statement and Joint Proxy Statement/Prospectus to be included therein; the expected timing of the closing of the proposed transaction; the ability of the parties to complete the proposed transaction considering the various closing conditions; the expected benefits of the proposed transaction; the competitive ability and position of the combined company; and any assumptions underlying any of the foregoing, ~~Inc~~are forward-looking statements. Important factors that could cause actual results to differ materially from Revolution Medicines’ and EQRx’s plans, estimates or expectations described in such forward-looking statements could include, but are not limited to: (~~formerly~~i) the ~~known~~risk that the proposed transaction may not be completed in a timely manner or at all, which may adversely affect Revolution Medicines’ and EQRx’s businesses and the price of their respective securities; (ii) uncertainties as to the timing of the consummation of the proposed transaction; (iii) the potential failure to receive, on a timely basis or otherwise, the required approvals of the proposed transaction, including stockholder approvals by both Revolution Medicines’ stockholders and EQRx’s stockholders, ~~Inc.)~~and the potential failure to ~~deliver~~satisfy upthe other conditions to 50the consummation of the transaction; (iv) that the proposed transaction may involve unexpected costs,~~000~~ liabilities or delays; (v) the effect of the announcement,~~000~~ ~~shares~~pendency or completion of the proposed transaction on each of Revolution Medicines’ or EQRx’s ~~Common~~ability ~~Stock~~to attract, motivate, retain and hire key personnel and maintain relationships with customers, distributors, suppliers and others with whom Revolution Medicines or EQRx does business, or on Revolution Medicines’ or EQRx’s operating results and business generally; (vi) that the ~~terms~~proposed transaction may divert management’s attention from each of Revolution Medicines’ and ~~subject~~EQRx’s ongoing business operations; (vii) the risk of any legal proceedings related to the ~~conditions~~proposed ~~specified~~transaction inor otherwise, or the impact of the proposed transaction thereupon, including resulting expense or delay; (viii) that Revolution Medicines or EQRx ~~DeSPAC~~may be adversely affected by other economic, business and/or competitive factors; (ix) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement (relating to the proposed “transaction, including in circumstances which would require Revolution Medicines or EQRx ~~Earn-Out”~~to pay a termination fee; (x). the risk ~~Each~~that ~~share~~restrictions during the pendency of the proposed transaction may impact Revolution Medicines’ or EQRx’s ~~Common~~ability to ~~Stock~~pursue certain business opportunities or strategic transactions; (xi) the risk that isRevolution ~~issued~~Medicines ~~and~~or ~~outstanding~~EQRx ~~immediately~~may ~~prior~~be unable to obtain governmental and regulatory approvals required for the ~~Effective~~proposed ~~Time~~transaction, or that required governmental and ~~held~~regulatory approvals may delay the consummation of the proposed transaction or result in ~~escrow~~the ~~subject~~imposition of conditions that could reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the ~~EQRx~~proposed ~~Earn-Out~~transaction; ~~will~~(xii) the risk that the anticipated benefits of the proposed transaction may otherwise not be ~~converted~~fully realized or may take longer to realize than expected; (xiii) the impact of legislative, regulatory, economic, competitive and technological changes; (xiv) risks relating to the value of Revolution Medicines securities to be issued in the ~~same~~proposed ~~manner~~transaction; (xv) the risk that integration of the proposed transaction post-closing may not occur as ~~all~~anticipated ~~other~~or ~~shares~~the combined company may not be able to achieve the growth prospects expected from the transaction; (xvi) the effect of the announcement, pendency or completion of the proposed transaction on the market price of the common stock of each of Revolution Medicines and the common stock and publicly traded warrants of EQRx; ~~Common~~(xvii) the ~~Stock~~implementation ~~under~~of each of Revolution Medicines’ and EQRx’s business model and strategic plans for product candidates and pipeline, and challenges inherent in developing, commercializing, manufacturing, launching, marketing and selling potential existing and new products; (xviii) the ~~Merger~~scope, ~~Agreement.~~progress, ~~Prior~~results toand ~~signing~~costs of developing Revolution Medicines’ and EQRx’s product candidates and any future product candidates, including conducting preclinical studies and clinical trials, and otherwise related to the research and development of Revolution Medicines’ and EQRx’s pipeline; ~~delivered~~(xix) the ~~signed~~timing ~~waivers~~and costs involved in obtaining and ~~releases~~maintaining ~~from~~regulatory ~~legacy~~approval for Revolution Medicines’ and EQRx’s ~~International~~current or future product candidates, ~~Inc.~~and ~~stockholders~~any ~~holding~~related ~~rights~~restrictions, limitations and/or warnings in the label of an approved product; (xx) the market for, adoption (including rate and degree of market acceptance) and pricing and reimbursement of Revolution Medicines’ and EQRx’s product candidates and their respective abilities to compete with ~~respect~~therapies and procedures that are rapidly growing and evolving; (xxi) uncertainties in contractual relationships, including collaborations, partnerships, licensing or other arrangements and the performance of third-party suppliers and manufacturers; (xxii) the ability of each of Revolution Medicines and EQRx to atestablish ~~least~~and amaintain ~~majority~~intellectual property protection for products or avoid or defend claims of infringement; (xxiii) exposure to inflation, currency rate and interest rate fluctuations and risks associated with doing business locally and internationally, as well as fluctuations in the ~~shares~~market ~~subject~~price of each of Revolution Medicines’ and EQRx’s traded securities; (xxiv) risks relating to competition within the industry in which each of Revolution Medicines and EQRx ~~Earn-Out~~operate; (xxv) the unpredictability and severity of catastrophic events, ~~pursuant~~including, but not limited to, ~~which~~acts ~~such~~of ~~holders~~terrorism ~~have~~or ~~waived~~outbreak of war or hostilities; (~~effective~~xxvi) whether ~~immediately~~the ~~prior~~termination of EQRx’s license agreements and/or discovery collaboration agreements may impact its or Revolution Medicines’ ability to license in additional programs in the ~~Effective~~future ~~Time~~and the risk of delays or unforeseen costs in terminating such arrangements; (xxvii) ~~their~~risks that ~~respective~~restructuring ~~rights~~costs toand ~~receive~~charges may be greater than anticipated or incurred in different periods than anticipated; (xxviii) the risk ~~applicable~~that ~~shares~~EQRx’s ~~subject~~restructuring efforts may adversely affect its programs and its ability to recruit and retain skilled and motivated personnel, and may be distracting to employees and management; and (xxix) the risk that EQRx’s ~~Earn~~restructuring or wind-~~Out~~down efforts may negatively impact its business operations and reputation with or ability to serve counterparties or may take longer to realize than expected, as well as each of Revolution Medicines’ and EQRx’s response to any of the aforementioned factors. Additional factors that may affect the future results of Revolution Medicines and EQRx are set forth in their respective filings with the U.S. Securities and Exchange Commission (the “SEC”), including each of Revolution Medicines’ and EQRx’s most recently filed Annual Reports on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other ~~right~~filings with ~~respect~~the toSEC, which are available on the SEC’s website at www.sec.gov. See in particular Item 1A of Revolution Medicines’ Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 under the heading “Risk Factors,” and Item 1A of each of EQRx’s ~~Earn~~Annual Report on Form 10-~~Out~~K for the fiscal year ended December 31, 2022 and Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 under the headings “Risk Factors.” The risks and uncertainties described above and in the SEC filings cited above are not exclusive and further information concerning Revolution Medicines and EQRx and their respective businesses, including factors that potentially could materially affect their respective businesses, financial conditions or operating results, may ~~obtain~~emerge ~~additional~~from ~~waivers~~time ~~prior~~to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. Readers should also carefully review the risk factors described in other documents that Revolution Medicines and EQRx ~~Stockholders~~file ~~Meeting~~from time to time with the SEC. Except as required by law, each of Revolution Medicines and EQRx assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

The “Exchange Ratio” will be determined by dividing the aggregate number of shares of Parent Common Stock to be issued as Merger Consideration by the number of shares of EQRx Common Stock outstanding immediately prior to the Effective Time, determined in accordance with the Merger Agreement. The number of shares of EQRx Common Stock outstanding for purposes of determining the Exchange Ratio will (i) take into account the number of shares of EQRx Common Stock subject to EQRx Options, EQRx RSU Awards and EQRx Restricted Stock that will convert into shares of Parent Common Stock in the Merger, (ii) include 10% of the shares of EQRx Common Stock subject to EQRx Warrants and (iii) include 10% of the shares of EQRx Common Stock subject to the EQRx Earn-Out (to the extent not waived by the applicable EQRx Earn-Out holder).

Governance

The Merger Agreement provides that, upon the closing of the Mergers, the board of directors of Revolution Medicines will be comprised of ten members, including one independent director from the board of directors of EQRx designated by Revolution Medicines and EQRx. Such director designee will be assigned to Class II of the board of directors of Revolution Medicines, the current term of which will expire at the annual meeting of Revolution Medicines’ stockholders to be held in 2025.

Conditions to the Mergers

The consummation of the Mergers is subject to customary closing conditions, including (i) the adoption of the Merger Agreement by the affirmative vote of the holders of a majority of the shares of EQRx Common Stock outstanding on the record date for the EQRx Stockholders Meeting; (ii) the approval of the issuance of shares of the Parent Common Stock in connection with the First Merger (the “Share Issuance”) by the affirmative vote of the holders of a majority in voting power of the votes cast at the special meeting of stockholders of Revolution Medicines (the “Revolution Medicines Stockholders Meeting”); (iii) the absence of any adverse law or order promulgated, enforced, enacted or issued by any governmental entity that prohibits, restrains or makes illegal the consummation of the Merger; (iv) the shares of the Parent Common Stock to be issued in the First Merger being approved for listing on the Nasdaq Global Select Market; (v) the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (if applicable); (vi) the U.S. Securities and Exchange Commission (the “SEC”) having declared effective the Registration Statement on Form S-4 filed by Revolution Medicines, which will contain the joint proxy statement/prospectus of the parties in connection with the Mergers; (vii) subject to certain materiality exceptions, the accuracy of certain representations and warranties of each of EQRx and Revolution Medicines contained in the Merger Agreement and the compliance by each party with the covenants contained in the Merger Agreement; and (viii) the absence of a continuing material adverse effect with respect to each of EQRx and Revolution Medicines. The parties expect that the Mergers will be completed in November 2023, subject to satisfaction of customary closing conditions, including approval by each of Revolution Medicines’ and EQRx’s stockholders.

Certain Other Terms of the Merger Agreement

EQRx, Revolution Medicines, Merger Sub I and Merger Sub II each made certain representations, warranties and covenants in the Merger Agreement, including, among other things, covenants by (i) EQRx to use reasonable best efforts to conduct its business consistent with a mutually agreed operating and capital expenditure budget and use commercially reasonable efforts to wind down certain mutually agreed programs, and to refrain from taking certain actions specified in the Merger Agreement, and (ii) Revolution Medicines to use commercially reasonable efforts to conduct its business in the ordinary course, and to refrain from taking certain actions specified in the Merger Agreement, in each case, during the period between the execution of the Merger Agreement and consummation of the Mergers. The parties to the Merger Agreement also agreed to use reasonable best efforts to cause the conditions of the Mergers to be satisfied and to consummate the Mergers.

Neither EQRx nor Revolution Medicines is permitted to solicit, initiate or knowingly encourage or induce, or take any other action designed to facilitate, any competing transaction proposals from third parties or to engage in discussions or negotiations with third parties regarding any competing transaction proposals, subject to certain exceptions. Each of EQRx’s or Revolution Medicines’ board of directors may change its recommendation to its stockholders in response to a superior proposal or an intervening event if such board of directors determines in good faith that the failure to take such action would be inconsistent with the directors’ fiduciary duties under applicable law.

The Merger Agreement provides for certain termination rights for both EQRx and Revolution Medicines, including the right of either party to terminate the Merger Agreement if the First Merger has not been consummated prior to 12:00 a.m. Eastern Time on January 31, 2024. Upon termination of the Merger Agreement under certain specified circumstances, including (i) the termination of the Merger Agreement by EQRx or Revolution Medicines in order to enter into an alternative transaction constituting a superior proposal or (y) the termination of the Merger Agreement by the other party due to a change in recommendation of EQRx’s or Revolution Medicines’ board of directors to its stockholders, EQRx or Revolution Medicines may be required to pay the other party a termination fee of $25.0 million (in the case of a termination fee payable by EQRx) or $65.0 million (in the case of a termination fee payable by Revolution Medicines). In addition, if the Merger Agreement is terminated due to either party’s failure to obtain the requisite stockholder vote under circumstances in which a termination fee is not payable, EQRx or Revolution Medicines may be required to pay the other party an expense reimbursement of up to $10.0 million.

The foregoing description of the material terms of the Merger Agreement does not purport to be complete and is subject to, and is qualified in its entirety by, reference to the Merger Agreement, which is filed as Exhibit 2.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The Merger Agreement has been attached as an exhibit to this report to provide investors and security holders with information regarding its terms. It is not intended to provide any other factual information about EQRx or Revolution Medicines or to modify or supplement any factual disclosures about EQRx or Revolution Medicines in their respective SEC filings. The Merger Agreement includes representations, warranties and covenants of EQRx and Revolution Medicines made solely for the purposes of the Merger Agreement and which may be subject to important qualifications and limitations agreed to by EQRx and Revolution Medicines in connection with the negotiated terms of the Merger Agreement. Moreover, some of those representations and warranties may not be accurate or complete as of any specified date, may be subject to certain disclosures between the parties and a contractual standard of materiality different from those generally applicable to EQRx’s or Revolution Medicines’ SEC filings. In addition, the representations and warranties were made for purposes of allocating risk among the parties to the Merger Agreement and should not be relied upon as establishing factual matters.

Voting Agreements

Simultaneously with the execution of the Merger Agreement, Revolution Medicines entered into voting agreements, each in substantially similar form, with certain of the directors and executive officers of EQRx (and stockholders of EQRx with which such directors and executive officers are affiliated) who hold more than 40% of the voting shares of EQRx (collectively, the “EQRx Supporting Stockholders” and such agreements, collectively, the “EQRx Voting Agreements”) and EQRx entered into voting agreements, each in substantially similar form, with certain of the directors and executive officers of Revolution Medicines (and stockholders of Revolution Medicines with which such directors and executive officers are affiliated) who hold approximately 8% of the voting shares of Parent Common Stock (collectively, the “Revolution Medicines Supporting Stockholders” and such agreements, collectively, the “Revolution Medicines Voting Agreements”).

Pursuant to the EQRx Voting Agreements, each EQRx Supporting Stockholder has agreed, among other things, to vote or cause to be voted its respective shares of beneficially owned EQRx Common Stock (i) in favor of the Merger Agreement and the transactions contemplated by the Merger Agreement, including the Mergers, and (ii) against (x) any action or agreement that would reasonably be expected to result in any of the closing conditions to be performed by EQRx under the Merger Agreement not being fulfilled and (y) any competing transaction proposal (as further described in the EQRx Voting Agreements), or any agreement, transaction or other matter that is intended to, or would reasonably be expected to, materially impede, materially interfere with or materially and adversely affect the consummation of the Mergers and the other transactions contemplated by the Merger Agreement. The EQRx Voting Agreements cannot be amended without Revolution Medicines’ consent.

Pursuant to Revolution Medicines Voting Agreements, each Revolution Medicines Supporting Stockholder has agreed, among other things, to vote or cause to be voted its respective shares of beneficially owned Parent Common Stock (i) in favor of the Share Issuance and (ii) against (x) any action or agreement that would reasonably be expected to result in any of the closing conditions to be performed by Revolution Medicines under the Merger Agreement not being fulfilled and (y) any competing transaction proposal (as further described in Revolution Medicines Voting Agreements), or any agreement, transaction or other matter that is intended to, or would reasonably be expected to, materially impede, materially interfere with or materially and adversely affect the consummation of the Mergers and the other transactions contemplated by the Merger Agreement. Revolution Medicines Voting Agreements cannot be amended without EQRx’s consent.

The foregoing description of the material terms of the EQRx Voting Agreements and Revolution Medicines Voting Agreements does not purport to be complete and is subject to, and qualified in its entirety by, reference to the form of Revolution Medicines Voting Agreement and the form of EQRx Voting Agreement, which are filed as Exhibit 10.1 and Exhibit 99.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

Lock-up Agreements

Simultaneously with the execution of the Merger Agreement, Revolution Medicines entered into lock-up agreements, each in substantially similar form, with each of the EQRx Supporting Stockholders and each of Revolution Medicines Supporting Stockholders (collectively, the “Lock-up Agreements”).

Pursuant to the Lock-up Agreements, each EQRx Supporting Stockholder and each Revolution Medicines Supporting Stockholder (together, the “Lock-up Parties”) has agreed, from the Effective Time until 11:59 p.m. Eastern Time on the 90th calendar day after the date on which the transactions contemplated by the Merger Agreement are consummated (the “Lock-up Period”), among other things, not to, subject to certain exceptions, sell, transfer or otherwise dispose of any shares of Parent Common Stock, including shares of Parent Common Stock received as Merger Consideration pursuant to the Merger Agreement, beneficially owned by such EQRx Supporting Stockholder or Revolution Medicines Supporting Stockholder after the Effective Time, as applicable. Notwithstanding the foregoing, beginning at 11:59 p.m. Eastern Time on the 30th calendar day after the date on which the transactions contemplated by the Merger Agreement are consummated, 20% of the shares of Parent Common Stock beneficially owned by the Lock-up Parties as of the Effective Time, exclusive of shares of Parent Common Stock acquired by the Lock-up Parties during the Lock-up Period, may be sold, transferred or otherwise disposed of in accordance with the terms of the Lock-up Agreements.

The foregoing description of the material terms of the Lock-up Agreements does not purport to be complete and is subject to, and qualified in its entirety by, reference to the form of Lock-up Agreement, which is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure

On August 1, 2023, Revolution Medicines and EQRx issued a joint press release announcing the entrance into the Merger Agreement described in Item 1.01 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.3 to this Current Report on Form 8-K.

The information contained in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.2 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 8.01 Other Events

In line with Revolution Medicines’ continued prioritization and focus of its resources on novel drug mechanisms of action targeting RAS-addicted cancers, Revolution Medicines does not intend to advance EQRx’s research and development portfolio following consummation of the Mergers. EQRx is expected to commence a process to wind down these programs and return the associated intellectual property to its partner on each.

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of federal securities laws, including the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and expectations of management of Revolution Medicines and EQRx, in light of historical results and trends, current conditions and potential future developments, and are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as “anticipate,” “expect,” “project,” “intend,” “believe,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “forecast,” “guidance,” “predict,” “possible,” “potential,” “pursue,” “likely,” and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. All statements, other than

historical facts, including express or implied statements regarding the proposed transaction; the conversion of equity interests contemplated by the Merger Agreement; the issuance of common stock of Revolution Medicines contemplated by the Merger Agreement; the expected filing by Revolution Medicines of a registration statement and Joint Proxy Statement/Prospectus to be included therein; the expected timing of the closing of the proposed transaction; the ability of the parties to complete the proposed transaction considering the various closing conditions; the expected benefits of the proposed transaction; the competitive ability and position of the combined company; Revolution Medicines’ expectation to not advance EQRx’s research and development portfolio following closing of the proposed transaction; EQRx’s expectation to wind down its programs; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from Revolution Medicines’ and EQRx’s plans, estimates or expectations described in such forward-looking statements could include, but are not limited to: (i) the risk that the proposed transaction may not be completed in a timely manner or at all, which may adversely affect Revolution Medicines’ and EQRx’s businesses and the price of their respective securities; (ii) uncertainties as to the timing of the consummation of the proposed transaction; (iii) the potential failure to receive, on a timely basis or otherwise, the required approvals of the proposed transaction, including stockholder approvals by both Revolution Medicines’ stockholders and EQRx’s stockholders, and the potential failure to satisfy the other conditions to the consummation of the transaction; (iv) that the proposed transaction may involve unexpected costs, liabilities or delays; (v) the effect of the announcement, pendency or completion of the proposed transaction on each of Revolution Medicines’ or EQRx’s ability to attract, motivate, retain and hire key personnel and maintain relationships with customers, distributors, suppliers and others with whom Revolution Medicines or EQRx does business, or on Revolution Medicines’ or EQRx’s operating results and business generally; (vi) that the proposed transaction may divert management’s attention from each of Revolution Medicines’ and EQRx’s ongoing business operations; (vii) the risk of any legal proceedings related to the proposed transaction or otherwise, or the impact of the proposed transaction thereupon, including resulting expense or delay; (viii) that Revolution Medicines or EQRx may be adversely affected by other economic, business and/or competitive factors; (ix) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement relating to the proposed transaction, including in circumstances which would require Revolution Medicines or EQRx to pay a termination fee; (x) the risk that restrictions during the pendency of the proposed transaction may impact Revolution Medicines’ or EQRx’s ability to pursue certain business opportunities or strategic transactions; (xi) the risk that Revolution Medicines or EQRx may be unable to obtain governmental and regulatory approvals required for the proposed transaction, or that required governmental and regulatory approvals may delay the consummation of the proposed transaction or result in the imposition of conditions that could reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the proposed transaction; (xii) the risk that the anticipated benefits of the proposed transaction may otherwise not be fully realized or may take longer to realize than expected; (xiii) the impact of legislative, regulatory, economic, competitive and technological changes; (xiv) risks relating to the value of Revolution Medicines securities to be issued in the proposed transaction; (xv) the risk that integration of the proposed transaction post-closing may not occur as anticipated or the combined company may not be able to achieve the growth prospects expected from the transaction; (xvi) the effect of the announcement, pendency or completion of the proposed transaction on the market price of the common stock of each of Revolution Medicines and the common stock and publicly traded warrants of EQRx; (xvii) the implementation of each of Revolution Medicines’ and EQRx’s business model and strategic plans for product candidates and pipeline, and challenges inherent in developing, commercializing, manufacturing, launching, marketing and selling potential existing and new products; (xviii) the scope, progress, results and costs of developing Revolution Medicines’ and EQRx’s product candidates and any future product candidates, including conducting preclinical studies and clinical trials, and otherwise related to the research and development of Revolution Medicines’ and EQRx’s pipeline; (xix) the timing and costs involved in obtaining and maintaining regulatory approval for Revolution Medicines’ and EQRx’s current or future product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product; (xx) the market for, adoption (including rate and degree of market acceptance) and pricing and reimbursement of Revolution Medicines’ and EQRx’s product candidates and their respective abilities to compete with therapies and procedures that are rapidly growing and evolving; (xxi) uncertainties in contractual relationships, including collaborations, partnerships, licensing or other arrangements and the performance of third-party suppliers and manufacturers; (xxii) the ability of each of Revolution Medicines and EQRx to establish and maintain intellectual property protection for products or avoid or defend claims of infringement; (xxiii) exposure to inflation, currency rate and interest rate fluctuations and risks associated with doing business locally and internationally, as well as fluctuations in the market price of each of Revolution Medicines’ and EQRx’s traded securities; (xxiv) risks relating to competition within the industry in which each of Revolution Medicines and EQRx operate; (xxv) the unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities; (xxvi) whether the termination of EQRx’s license agreements and/or discovery collaboration agreements may impact its or Revolution Medicines’ ability to license in additional programs in the future and the risk of delays or unforeseen costs in terminating such arrangements; (xxvii) risks that restructuring costs and charges may be

greater than anticipated or incurred in different periods than anticipated; (xxviii) the risk that EQRx’s restructuring efforts may adversely affect its programs and its ability to recruit and retain skilled and motivated personnel, and may be distracting to employees and management; and (xxix) the risk that EQRx’s restructuring or wind-down efforts may negatively impact its business operations and reputation with or ability to serve counterparties or may take longer to realize than expected, as well as each of Revolution Medicines’ and EQRx’s response to any of the aforementioned factors. Additional factors that may affect the future results of Revolution Medicines and EQRx are set forth in their respective filings with the SEC, including each of Revolution Medicines’ and EQRx’s most recently filed Annual Reports on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available on the SEC’s website at www.sec.gov. See in particular Item 1A of Revolution Medicines’ Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 under the heading “Risk Factors,” and Item 1A of each of EQRx’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 under the headings “Risk Factors.” The risks and uncertainties described above and in the SEC filings cited above are not exclusive and further information concerning Revolution Medicines and EQRx and their respective businesses, including factors that potentially could materially affect their respective businesses, financial conditions or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. Readers should also carefully review the risk factors described in other documents that Revolution Medicines and EQRx file from time to time with the SEC. Except as required by law, each of Revolution Medicines and EQRx assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

Additional Information and Where to Find It

In connection with the proposed transaction, Revolution Medicines and EQRx plan to file with the SEC and mail or otherwise provide to their respective security holders a joint proxy statement/prospectus regarding the proposed transaction (as amended or supplemented from time to time, the “Joint Proxy Statement/Prospectus”). INVESTORS AND REVOLUTION MEDICINES’ AND EQRX’S RESPECTIVE SECURITY HOLDERS ARE URGED TO CAREFULLY READ THE JOINT PROXY STATEMENT/PROSPECTUS IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE AND ANY OTHER DOCUMENTS FILED BY EACH OF REVOLUTION MEDICINES AND EQRX WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION.

Revolution Medicines’ investors and security holders may obtain a free copy of the Joint Proxy Statement/Prospectus and other documents that Revolution Medicines files with the SEC (when available) from the SEC’s website at www.sec.gov and Revolution Medicines’ website at ir.revmed.com. In addition, the Joint Proxy Statement/Prospectus and other documents filed by Revolution Medicines with the SEC (when available) may be obtained from Revolution Medicines free of charge by directing a request to Eric Bonach, H/Advisors Abernathy at eric.bonach@h-advisors.global.

EQRx’s investors and security holders may obtain a free copy of the Joint Proxy Statement/Prospectus and other documents that EQRx files with the SEC (when available) from the SEC’s website at www.sec.gov and EQRx’s website at investors.eqrx.com. In addition, the Joint Proxy Statement/Prospectus and other documents filed by EQRx with the SEC (when available) may be obtained from EQRx free of charge by directing a request to EQRx’s Investor Relations at investors@eqrx.com.

No Offer or Solicitation

This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Participants in the Solicitation

Revolution Medicines, EQRx and their respective directors, executive officers, other members of management, certain employees and other persons may be deemed to be participants in the solicitation of proxies from the security holders of Revolution Medicines and EQRx in connection with the proposed transaction. Security holders may obtain information regarding the names, affiliations and interests of Revolution Medicines’ directors and executive officers in Revolution Medicines’ Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on February 27, 2023, and Revolution Medicines’ definitive proxy statement on Schedule 14A for its 2023 annual meeting of stockholders, which was filed with the SEC on April 26, 2023. To the extent holdings of Revolution Medicines’ securities by Revolution Medicines’ directors and executive officers have changed since the amounts set forth in such proxy statement, such changes have been or will be reflected on subsequent Statements of Changes in Beneficial Ownership on Form 4 filed with the SEC. Security holders may obtain information regarding the names, affiliations and interests of EQRx’s directors and executive officers in EQRx’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on February 23, 2023, and in certain of EQRx’s Current Reports on Form 8-K. To the extent holdings of EQRx’s securities by EQRx’s directors and executive officers have changed since the amounts set forth in such Annual Report on Form 10-K, such changes have been or will be reflected on subsequent Statements of Changes in Beneficial Ownership on Form 4 filed with the SEC. Additional information regarding the interests of such individuals in the proposed transaction will be included in the Joint Proxy Statement/Prospectus relating to the proposed transaction when it is filed with the SEC. These documents (when available) may be obtained free of charge from the SEC’s website at www.sec.gov, Revolution Medicines’ website at www.revmed.com and EQRx’s website at www.eqrx.com.

~~Item~~SIGNATURES ~~9.01 Financial Statements and Exhibits~~

(d) Exhibits.

EXHIBITNUMBER		DESCRIPTION
2.1*		Agreement and Plan of Merger, dated July 31, 2023, by and among Revolution Medicines, Inc., EQRx, Inc., Equinox Merger Sub I, Inc. and Equinox Merger Sub II LLC.
10.1		Form of Voting Agreement, dated as of July 31, 2023, by and among Revolution Medicines, Inc. and certain stockholders of EQRx, Inc.
99.1		Form of Voting Agreement, dated as of July 31, 2023, by and among EQRx, Inc. and certain stockholders of Revolution Medicines, Inc.
99.2		Form of Lock-Up Agreement, dated as of July 31, 2023, by and between Revolution Medicines, Inc. and certain stockholders of EQRx, Inc. and Revolution Medicines, Inc.
99.3**		Joint Press Release of EQRx, Inc. and Revolution Medicines, Inc., dated August 1, 2023.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

* The schedules to the Agreement and Plan of Merger have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K. Registrant will furnish copies of such schedules to the SEC upon request by the Commission; provided, that Revolution Medicines may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules so furnished.

** Furnished herewith.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			EQRx, Inc.
Date: August 3, 2023		EQRX, INC.
Date: August 1, 2023			By:	/s/ Melanie Nallicheri
	By:	/s/ Melanie Nallicheri
	Name:	Melanie Nallicheri	~~Name:~~	~~Melanie Nallicheri~~
	Title:	President and Chief Executive Officer	~~Title:~~	~~President and Chief Executive Officer~~

Filing Compare · EQRx, Inc.